CD19-7×19 CAR-T / Zhejiang University - LARVOL DELTA

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma (clinicaltrials.gov) - P=N/A | N=39 | Completed | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Oct 2020 ➔ Oct 2024

Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CCL19 • IL7

Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma (PubMed, Zhonghua Xue Ye Xue Za Zhi) - "Objective: This study systematically explore the efficacy and safety of fourth-generation chimeric antigen receptor T-cells (CAR-T), which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19, in relapsed or refractory large B-cell lymphoma. Cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome were controllable, and no immune-related adverse reactions occurred. Autologous 7×19 CAR-T combined with tirelizumab for treating relapsed or refractory large B-cell lymphoma achieved good efficacy with controllable adverse reactions."

Journal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCL19 • CD19 • IL7

CICPD: CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P1 | N=24 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting ➔ Enrolling by invitation

Enrollment status • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCL19 • CD19 • CD20 • IL7 • PD-1

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Ningbo No. 1 Hospital

New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741) (ASH 2021) - P1 | "CD19- 7×19 CA R-T cells were administrated at dose of 1 to 3 × 10 6 CAR-T cells/kg following lymphodepleting chemotherapies using fludarabine (30 mg/m 2 ) and cyclophosphamide (500 mg/m 2 ). At 30th day after modified T-cells infusion, patients received 6 cycles of anti-PD-1 antibody Tislelizumab (200mg) for every 3 weeks...However, it remains unclear whether long term remission rate can be achieved. Long term follow-up and additionally enrolled patients would be necessary."

CAR T-Cell Therapy • Clinical • Combination therapy • IO biomarker • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CCL19 • CD19 • CD8 • FDG PET • IL7